BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 29292693)

  • 1. Efficacy and safety of everolimus plus low-dose calcineurin inhibitor vs. mycophenolate mofetil plus standard-dose calcineurin inhibitor in renal transplant recipients: A systematic review and meta-analysis
.
    He L; Deng J; Yang B; Jiang W
    Clin Nephrol; 2018 May; 89(5):336-344. PubMed ID: 29292693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of mycophenolate mofetil and calcineurin inhibitor as maintenance immunosuppression for kidney transplant recipients: A meta-analysis of randomized controlled trials.
    Deng J; Lu Y; He L; Ou J; Xie H
    Turk J Med Sci; 2021 Jun; 51(3):1080-1091. PubMed ID: 33356028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
    Montero N; Quero M; Melilli E; Pérez-Sáez MJ; Redondo-Pachón D; Bestard O; Crespo M; Cruzado JM; Pascual J
    Transplantation; 2019 Oct; 103(10):2031-2056. PubMed ID: 31343574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
    Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
    Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study.
    Citterio F; Henry M; Kim DY; Kim MS; Han DJ; Kenmochi T; Mor E; Tisone G; Bernhardt P; Hernandez Gutierrez MP; Watarai Y
    Expert Opin Drug Saf; 2020 Oct; 19(10):1339-1348. PubMed ID: 32633157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
    Lin M; Mittal S; Sahebjam F; Rana A; Sood GK
    Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y; Shaffer D; Kaplan B; Kim DY; Luan FL; Peddi VR; Shihab F; Tomlanovich S; Yilmaz S; McCague K; Patel D; Mulgaonkar S
    Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
    Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
    PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
    de Boer SE; Sanders JSF; Bemelman FJ; Betjes MGH; Burgerhof JGM; Hilbrands L; Kuypers D; van Munster BC; Nurmohamed SA; de Vries APJ; van Zuilen AD; Hesselink DA; Berger SP
    BMC Nephrol; 2021 Jun; 22(1):208. PubMed ID: 34078323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal growth on an everolimus- versus an MMF-based steroid-free immunosuppressive regimen in paediatric renal transplant recipients.
    Billing H; Burmeister G; Plotnicki L; Ahlenstiel T; Fichtner A; Sander A; Höcker B; Tönshoff B; Pape L
    Transpl Int; 2013 Sep; 26(9):903-9. PubMed ID: 23865768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials.
    Yan HL; Zong HT; Cui YS; Li N; Zhang Y
    Transplant Proc; 2014 Jun; 46(5):1302-13. PubMed ID: 24935293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
    Mallat SG; Tanios BY; Itani HS; Lotfi T; McMullan C; Gabardi S; Akl EA; Azzi JR
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1321-1336. PubMed ID: 28576905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation.
    Nelson LM; Andreassen AK; Andersson B; Gude E; Eiskjær H; Rådegran G; Dellgren G; Gullestad L; Gustafsson F
    Transplantation; 2017 Nov; 101(11):2793-2800. PubMed ID: 28230646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study.
    Sterneck M; Kaiser GM; Heyne N; Richter N; Rauchfuss F; Pascher A; Schemmer P; Fischer L; Klein CG; Nadalin S; Lehner F; Settmacher U; Gotthardt D; Loss M; Ladenburger S; Wimmer P; Dworak M; Schlitt HJ
    Clin Transplant; 2016 Jun; 30(6):741-8. PubMed ID: 27160359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
    Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis.
    Moore J; Middleton L; Cockwell P; Adu D; Ball S; Little MA; Ready A; Wheatley K; Borrows R
    Transplantation; 2009 Feb; 87(4):591-605. PubMed ID: 19307799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
    Berger SP; Sommerer C; Witzke O; Tedesco H; Chadban S; Mulgaonkar S; Qazi Y; de Fijter JW; Oppenheimer F; Cruzado JM; Watarai Y; Massari P; Legendre C; Citterio F; Henry M; Srinivas TR; Vincenti F; Gutierrez MPH; Marti AM; Bernhardt P; Pascual J;
    Am J Transplant; 2019 Nov; 19(11):3018-3034. PubMed ID: 31152476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.
    Su L; Tam N; Deng R; Chen P; Li H; Wu L
    Int Urol Nephrol; 2014 Oct; 46(10):2035-44. PubMed ID: 25027805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial.
    Gaston RS; Kaplan B; Shah T; Cibrik D; Shaw LM; Angelis M; Mulgaonkar S; Meier-Kriesche HU; Patel D; Bloom RD
    Am J Transplant; 2009 Jul; 9(7):1607-19. PubMed ID: 19459794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathologic impacts of everolimus introduction on kidney transplant recipients.
    Nakamura T; Ushigome H; Takata T; Nakao T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Yoshimura N
    Transplant Proc; 2015 Apr; 47(3):630-4. PubMed ID: 25891700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.